Calcitonin (salmon)
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Calcitonin (salmon) and local guidelines before prescribing.
Peptide hormone
Mechanism
Inhibits osteoclast bone resorption.
Uses
Hypercalcaemia (short term), Paget disease, acute vertebral fracture pain.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Nausea, flushing, injection-site reaction, hypocalcaemia; tachyphylaxis.
Interactions
Few.
Contraindications and cautions
Hypocalcaemia
Monitoring
Calcium
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Escape from effect within days limits use in hypercalcaemia; long-term use linked to cancer risk.
More from the textbook: uses, cautions and other points
- Thyroid nodule, diarrhoea, raised calcitonin | Medullary carcinoma (screen for MEN2)
Endocrinology: Thyroid disease - Parafollicular (C) cells - make calcitonin (origin of medullary thyroid cancer - calcitonin and CEA are tumour markers; associated with MEN 2 and RET mutations).
Endocrine: Anatomy Physiology and Pharmacology - Calcitonin - lowers calcium a little; of minor importance in humans (but a tumour marker for medullary thyroid cancer).
Endocrine: Anatomy Physiology and Pharmacology - Hypercalcaemia treatment - IV fluids (0.9% saline) first, then IV bisphosphonate; steroids if vitamin D-driven (sarcoidosis, lymphoma); denosumab or calcitonin in some cases.
Endocrine: Anatomy Physiology and Pharmacology - Mechanism: A cancer of the parafollicular C cells (about 5% of thyroid cancers). These cells make calcitonin and do not take up iodine. About a quarter are hereditary , caused by RET mutations in MEN2A (with phaeochromocytoma and hyperparathyroidism) or MEN2B (with phaeochromocytoma, mucosal neuromas and a marfanoid habitus), or familial …
Endocrinology: Thyroid disease - Diarrhoea and flushing from calcitonin and other peptides.
Endocrinology: Thyroid disease - Serum calcitonin and CEA - tumour markers for diagnosis and follow-up.
Endocrinology: Thyroid disease - A 55-year-old man has a thyroid nodule, a calcitonin of 400 and a history of hypertensive episodes. Answer: Medullary carcinoma with suspected MEN2. RET testing; exclude phaeochromocytoma before thyroid surgery ; total thyroidectomy with neck dissection.
Endocrinology: Thyroid disease
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (3 mentions)
- Endocrinology: Thyroid disease (6 mentions)
- Endocrinology: Bone Medicine (2 mentions)
- Endocrinology: NETS and Hypoglycaemia (2 mentions)
- Haematology: Myeloma and Lymphoma (1 mention)
- Oncology: Principles (1 mention)
- Oncology: Emergencies (1 mention)
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Surgey: Breast and endocrine surgery (4 mentions)
- Acute Medicine: Electrolytes, acid–base, AKI and metabolic emergencies (1 mention)
- Clinical Genetics: Cancer genetics and inherited cardiovascular conditions (3 mentions)
- Physiology: Cells, tissues, homeostasis, fluids and acid–base balance (2 mentions)
- Biochemistry: Clinical biochemistry - interpreting laboratory tests (1 mention)
- Pathology: Immunopathology, amyloidosis, genetic and environmental disease (1 mention)
- 0230 (1 mention)
- Histology: Organ-system histology (2 mentions)